Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hypromellose; magnesium stearate; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red - colon cancer ,capecitabine is indicated for the adjuvant treatment of patients with dukes? stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated ,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - capecitabine, quantity: 500 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; microcrystalline cellulose; hypromellose; croscarmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red - colon cancer ,capecitabine is indicated for the adjuvant treatment of patients with dukes? stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated ,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - calcipotriol, quantity: 50 microgram/g; betamethasone dipropionate (equivalent: betamethasone, qty 500 microgram/g) - gel - excipient ingredients: nitrogen; hydrogenated castor oil; polyoxypropylene-11 stearyl ether; butylated hydroxytoluene; liquid paraffin; dl-alpha-tocopherol - topical treatment of scalp psoriasis. topical treatment of mild to moderate plaque psoriasis on the body in adults.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - diltiazem hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hydrogenated castor oil; aluminium hydroxide; methacrylic acid copolymer; purified talc; magnesium stearate; titanium dioxide; indigo carmine; methylcellulose; macrogol 400 - moderate to severe angina pectoris due to atherosclerotic coronary artery disease or coronary artery spasm (vasospastic angina).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diltiazem hydrochloride -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diltiazem hydrochloride -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - esmolol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium acetate trihydrate; glacial acetic acid - supraventricular tachycardia - for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol is also indicated in non-compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol is not intended for use in chronic settings where transfer to another agent is anticipated, or for treatment periods greater than 24 hours duration.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - promethazine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; sodium metabisulfite; glacial acetic acid; sodium acetate; water for injections - indication as 8 january 2004: promethazine hydrochloride injection bp is indicated for the following conditions: treatment of allergic reactions such as: uncomplicated allergic conditions of the immediate type, e.g. pruritus, urticaria and angioedema, when oral therapy is impossible or contraindicated. treatment and prevention of vomiting including: motion sickness; drug induced nausea; prevention and control of nausea and vomiting associated with certain types of anaesthesia and surgery, such as procedures with a high incidence of post-operative vomiting (e.g. gynaecological surgery, strabismus or middle ear surgery, and electroconvulsive therapy); in patients with a past history of motion sickness or post-operative vomiting; and in patients in whom avoidance of vomiting is crucial (e.g. neurosurgery and eye surgery). promethazine has sedative effects and it is also used in: pre-operative, post-operative and obstetric (during labour) sedation.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - esmolol hydrochloride, quantity: 2500 mg - injection, powder for - excipient ingredients: - supraventricular tachycardia,brevibloc (esmolol hcl) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. brevibloc is also indicated in non compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. brevibloc is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

lawley pharmaceuticals pty ltd - testosterone, quantity: 10 mg/ml - cream - excipient ingredients: almond oil; butylated hydroxytoluene; carbomer 940; cetomacrogol 1000; cetostearyl alcohol; citric acid; dl-alpha-tocopheryl acetate; trolamine; purified water; phenoxyethanol; propyl hydroxybenzoate; ethyl hydroxybenzoate; isobutyl hydroxybenzoate; butyl hydroxybenzoate; methyl hydroxybenzoate - androfeme 1 is indicated for the treatment of hypoactive sexual desire dysfunction (hsdd) in postmenopausal women. therapeutic intervention with androfeme 1 should only be initiated in women following failure of appropriate education and correction of modifiable biopsychosocial factors (which may include neuroendocrine imbalance, physical ill health or disease, interpersonal difficulties, psychological distress or specific cultural or religious beliefs), according to the international society for the study of women?s sexual health (isswsh) process of care (see figure 1).